{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:28:50Z","timestamp":1792535330331,"version":"4.5.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gout and chronic kidney disease (CKD) frequently coexist, but quality evidence to guide gout management in people with CKD is lacking. Use of urate-lowering therapy (ULT) in the context of advanced CKD varies greatly, and professional bodies have issued conflicting recommendations regarding the treatment of gout in people with concomitant CKD. As a result, confusion exists among medical professionals about the appropriate management of people with gout and CKD. This Consensus Statement from the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) discusses the evidence and\/or lack thereof for the management of gout in people with CKD and identifies key areas for research to address the challenges faced in the management of gout and CKD. These discussions, which address areas for research both in general as well as related to specific medications used to treat gout flares or as ULT, are supported by separately published G-CAN systematic literature reviews. This Consensus Statement is not intended as a guideline for the management of gout in CKD; rather, it analyses the available literature on the safety and efficacy of drugs used in gout management to identify important gaps in knowledge and associated areas for research.<\/jats:p>","DOI":"10.1038\/s41584-021-00657-4","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T22:06:40Z","timestamp":1627682800000},"page":"633-641","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0138-2912","authenticated-orcid":false,"given":"Lisa K.","family":"Stamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3060-4019","authenticated-orcid":false,"given":"Hamish","family":"Farquhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huai Leng","family":"Pisaniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5307-0254","authenticated-orcid":false,"given":"Ana B.","family":"Vargas-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0310-2304","authenticated-orcid":false,"given":"David B.","family":"Mount","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyon K.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Terkeltaub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8289-4922","authenticated-orcid":false,"given":"Catherine L.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo L.","family":"Gaffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,30]]},"reference":[{"key":"657_CR1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","volume":"11","author":"C Kuo","year":"2015","unstructured":"Kuo, C., Grainge, M., Zhang, W. & Doherty, M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat. Rev. Rheumatol. 11, 649\u2013662 (2015).","journal-title":"Nat. Rev. Rheumatol."},{"key":"657_CR2","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/art.40807","volume":"71","author":"M Chen-Xu","year":"2019","unstructured":"Chen-Xu, M., Yokose, C., Rai, S., Pillinger, M. & Choi, H. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends; The National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol. 71, 991\u2013999 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"657_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","volume":"125","author":"Y Zhu","year":"2012","unstructured":"Zhu, Y., Pandya, B. & Choi, H. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am. J. Med. 125, 679\u2013687 (2012).","journal-title":"Am. J. Med."},{"key":"657_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13075-015-0610-9","volume":"17","author":"M Roughley","year":"2015","unstructured":"Roughley, M., Belcher, J., Mallen, C. & Roddy, E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res. Ther. 17, 90 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"657_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-14-363","volume":"14","author":"N Dalbeth","year":"2013","unstructured":"Dalbeth, N., House, M., Horne, A. & Taylor, W. Reduced creatinine clearance is associated with early development of subcutaneous tophi in people with gout. BMC Musculoskelet. Disord. 14, 363 (2013).","journal-title":"BMC Musculoskelet. Disord."},{"key":"657_CR6","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.3899\/jrheum.131240","volume":"41","author":"C Lu","year":"2014","unstructured":"Lu, C. et al. Clinical characteristics of and relationship between metabolic components and renal function among patients with early-onset juvenile tophaceous gout. J. Rheumatol. 41, 1878\u20131883 (2014).","journal-title":"J. Rheumatol."},{"key":"657_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050046","volume":"7","author":"E Krishnan","year":"2012","unstructured":"Krishnan, E. Reduced glomerular function and prevalence of gout: NHANES 2009\u201310. PLoS ONE 7, e50046 (2012).","journal-title":"PLoS ONE"},{"key":"657_CR8","doi-asserted-by":"publisher","first-page":"R206","DOI":"10.1186\/ar2952","volume":"12","author":"N Busso","year":"2010","unstructured":"Busso, N. & So, A. Mechanisms of inflammation in gout. Arthritis Res. Ther. 12, R206 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"657_CR9","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1136\/annrheumdis-2014-206564","volume":"75","author":"T Cri\u0219an","year":"2016","unstructured":"Cri\u015fan, T. et al. Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra. Ann. Rheum. Dis. 75, 755\u2013762 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"657_CR10","doi-asserted-by":"publisher","first-page":"2180373","DOI":"10.1155\/2018\/2180373","volume":"2018","author":"S Mihai","year":"2018","unstructured":"Mihai, S. et al. Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome. J. Immunol. Res. 2018, 2180373 (2018).","journal-title":"J. Immunol. Res."},{"key":"657_CR11","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.2215\/CJN.00950208","volume":"3","author":"S Kato","year":"2008","unstructured":"Kato, S. et al. Aspects of immune dysfunction in end-stage renal disease. Clin. J. Am. Soc. Nephrol. 3, 1526\u20131533 (2008).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"657_CR12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000368940","volume":"39","author":"OM Akchurin","year":"2015","unstructured":"Akchurin, O. M. & Kaskel, F. Update on inflammation in chronic kidney disease. Blood Purif. 39, 84\u201392 (2015).","journal-title":"Blood Purif."},{"key":"657_CR13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrneph.2011.62","volume":"7","author":"V Krane","year":"2011","unstructured":"Krane, V. & Wanner, C. Statins, inflammation and kidney disease. Nat. Rev. Nephrol. 7, 385\u2013397 (2011).","journal-title":"Nat. Rev. Nephrol."},{"key":"657_CR14","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.kint.2020.08.024","volume":"99","author":"T Bardin","year":"2021","unstructured":"Bardin, T. et al. A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout. Kidney Int. 99, 218\u2013226 (2021).","journal-title":"Kidney Int."},{"key":"657_CR15","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1681\/ASN.2020040523","volume":"31","author":"M Sellmayr","year":"2020","unstructured":"Sellmayr, M. et al. Only hyperuricemia with crystalluria, but not asymptomatic hyperuricemia, drives progression of chronic kidney disease. J. Am. Soc. Nephrol. 31, 2773\u20132792 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"657_CR16","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1136\/annrheumdis-2019-215933","volume":"78","author":"D Bursill","year":"2019","unstructured":"Bursill, D. et al. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Ann. Rheum. Dis. 78, 1592\u20131600 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"657_CR17","first-page":"U109","volume":"115","author":"S Kumar","year":"2002","unstructured":"Kumar, S. & Gow, P. A survey of indications, results and complications of surgery for tophaceous gout. N. Z. Med. J. 115, U109 (2002).","journal-title":"N. Z. Med. J."},{"key":"657_CR18","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3899\/jrheum.071229","volume":"36","author":"M Becker","year":"2009","unstructured":"Becker, M. et al. Quality of life and disability in patients with treatment-failure gout. J. Rheumatol. 36, 1041\u20131048 (2009).","journal-title":"J. Rheumatol."},{"key":"657_CR19","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1093\/rheumatology\/kem246","volume":"46","author":"N Dalbeth","year":"2007","unstructured":"Dalbeth, N. et al. Tophaceous joint disease strongly predicts hand function in patients with gout. Rheumatology 46, 1804\u20131807 (2007).","journal-title":"Rheumatology"},{"key":"657_CR20","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1136\/ard.2007.081604","volume":"67","author":"JA Singh","year":"2008","unstructured":"Singh, J. A. & Strand, V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann. Rheum. Dis. 67, 1310\u20131316 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"657_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/RHU.0b013e3181b562f8","volume":"15","author":"I Hutton","year":"2009","unstructured":"Hutton, I., Gamble, G., Gow, P. & Dalbeth, N. Factors associated with recurrent hospital admissions for gout: a case-controlled study. J. Clin. Rheumatol. 15, 271\u2013274 (2009).","journal-title":"J. Clin. Rheumatol."},{"key":"657_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-017-1573-6","volume":"18","author":"J Singh","year":"2017","unstructured":"Singh, J. et al. Health care utilization in patients with gout: a prospective multicentre cohort study. BMC Musculoskelet. Disord. 18, 233 (2017).","journal-title":"BMC Musculoskelet. Disord."},{"key":"657_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.7326\/M16-0570","volume":"166","author":"A Qaseem","year":"2017","unstructured":"Qaseem, A., Harris, R. P., Forciea, M. & Clinical Guidelines Committee of the American College of Physicians. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann. Int. Med. 166, 58\u201368 (2017).","journal-title":"Ann. Int. Med."},{"key":"657_CR24","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1053\/j.ajkd.2017.01.055","volume":"70","author":"AB Vargas-Santos","year":"2017","unstructured":"Vargas-Santos, A. B. & Neogi, T. Management of gout and hyperuricaemia in CKD. Am. J. Kidney Dis. 70, 422\u2013439 (2017).","journal-title":"Am. J. Kidney Dis."},{"key":"657_CR25","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3899\/jrheum.170911","volume":"45","author":"L Stamp","year":"2018","unstructured":"Stamp, L. et al. Variability in the reporting of serum urate and flares in gout clinical trials: need for minimal reporting requirements. J. Rheumatol. 45, 419\u2013424 (2018).","journal-title":"J. Rheumatol."},{"key":"657_CR26","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.semarthrit.2019.11.002","volume":"50","author":"S Stewart","year":"2020","unstructured":"Stewart, S., Tallon, A., Taylor, W., Gaffo, A. & Dalbeth, N. How flare prevention outcomes are reported in gout studies: a systematic review and content analysis of randomized controlled trials. Semin. Arthritis Rheum. 50, 303\u2013313 (2020).","journal-title":"Semin. Arthritis Rheum."},{"key":"657_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette, P. et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann. Rheum. Dis. 76, 29\u201342 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"657_CR28","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"J FitzGerald","year":"2020","unstructured":"FitzGerald, J. et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res. 72, 744\u2013760 (2020).","journal-title":"Arthritis Care Res."},{"key":"657_CR29","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3899\/jrheum.200347","volume":"48","author":"L Stamp","year":"2021","unstructured":"Stamp, L., Taylor, W. & Gaffo, A. Variability in urate lowering therapy prescribing: a Gout, Hyperuricaemia and Crystal-Associated Arthritis disease Network (G-CAN) physician survey. J. Rheumatol. 48, 152\u2013153 (2021).","journal-title":"J. Rheumatol."},{"key":"657_CR30","first-page":"1646","volume":"33","author":"N Dalbeth","year":"2006","unstructured":"Dalbeth, N., Kumar, S., Stamp, L. K. & Gow, P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricaemia in patients with gout. J. Rheumatol. 33, 1646\u20131650 (2006).","journal-title":"J. Rheumatol."},{"key":"657_CR31","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1136\/annrheumdis-2012-201687","volume":"71","author":"M Doherty","year":"2012","unstructured":"Doherty, M. et al. Gout: why is this curable disease so seldom cured? Ann. Rheum. Dis. 71, 1765\u20131770 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"657_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s41927-019-0060-0","volume":"3","author":"DH Jaffe","year":"2019","unstructured":"Jaffe, D. H. et al. Incident gout and chronic kidney disease: healthcare utilization and survival. BMC Rheumatol. 3, 11 (2019).","journal-title":"BMC Rheumatol."},{"key":"657_CR33","doi-asserted-by":"publisher","first-page":"rkaa073","DOI":"10.1093\/rap\/rkaa073","volume":"5","author":"H Farquhar","year":"2021","unstructured":"Farquhar, H. et al. Efficacy and safety of urate-lowering therapy in people with kidney impairment: a GCAN-initiated literature review. Rheumatol. Adv. Pract. 5, rkaa073 (2021).","journal-title":"Rheumatol. Adv. Pract."},{"key":"657_CR34","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13075-021-02416-y","volume":"23","author":"H Pisaniello","year":"2021","unstructured":"Pisaniello, H. et al. Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review. Arthritis Res. Ther. 23, 130 (2021).","journal-title":"Arthritis Res. Ther."},{"key":"657_CR35","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1001\/jamacardio.2019.3201","volume":"4","author":"A Klauser","year":"2019","unstructured":"Klauser, A. et al. Dual-energy computed tomography detection of cardiovascular monosodium urate deposits in patients with gout. JAMA Cardiol. 4, 1019\u20131028 (2019).","journal-title":"JAMA Cardiol."},{"key":"657_CR36","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.3390\/jcm9103204","volume":"9","author":"P Khanna","year":"2020","unstructured":"Khanna, P., Johnson, R., Marder, B., LaMoreaux, B. & Kumar, A. Systemic urate deposition: an unrecognized complication of gout? J. Clin. Med. 9, 3204 (2020).","journal-title":"J. Clin. Med."},{"key":"657_CR37","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1136\/annrheumdis-2012-202421","volume":"73","author":"F Perez-Ruiz","year":"2014","unstructured":"Perez-Ruiz, F. et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann. Rheum. Dis. 73, 177\u2013182 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"657_CR38","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1159\/000045783","volume":"86","author":"F Perez-Ruiz","year":"2000","unstructured":"Perez-Ruiz, F., Calabozo, M., Herrero-Beites, A., Erauskin, G. & Pijoan, J. Improvement of renal function in patients with chronic gout after proper control of hyperuricaemia and gouty bouts. Nephron 86, 287\u2013291 (2000).","journal-title":"Nephron"},{"key":"657_CR39","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13075-017-1491-x","volume":"19","author":"L Stamp","year":"2017","unstructured":"Stamp, L. et al. The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized clinical trial. Arthritis Res. Ther. 19, 283 (2017).","journal-title":"Arthritis Res. Ther."},{"key":"657_CR40","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cct.2018.03.015","volume":"68","author":"S Timilsina","year":"2018","unstructured":"Timilsina, S. et al. Design and rationale for the Veterans Affairs \u201cCooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat\u201d trial. Contemp. Clin. Trials 68, 102\u2013108 (2018).","journal-title":"Contemp. Clin. Trials"},{"key":"657_CR41","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","volume":"76","author":"T Bardin","year":"2017","unstructured":"Bardin, T. et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann. Rheum. Dis. 76, 811\u2013820 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"657_CR42","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/art.39840","volume":"69","author":"K Saag","year":"2017","unstructured":"Saag, K. et al. Lesinurad combined with allopurinol: randomized, double-blind, placebo-controlled study in gout subjects with inadequate response to standard of care allopurinol (a US-based study). Arthritis Rheum. 69, 203\u2013212 (2017).","journal-title":"Arthritis Rheum."},{"key":"657_CR43","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"M Becker","year":"2005","unstructured":"Becker, M. et al. Febuxostat compared with allopurinol in patients with hyperuricaemia and gout. N. Engl. J. Med. 353, 2450\u20132461 (2005).","journal-title":"N. Engl. J. Med."},{"key":"657_CR44","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/rheumatology\/keu424","volume":"54","author":"F Araujo","year":"2015","unstructured":"Araujo, F. et al. Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains: a systematic literature review. Rheumatology 54, 981\u2013993 (2015).","journal-title":"Rheumatology"},{"key":"657_CR45","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1080\/14656566.2020.1856369","volume":"22","author":"KS Tang","year":"2021","unstructured":"Tang, K. S. & Shah, A. D. Nonsteroidal anti-inflammatory drugs in end-stage kidney disease: dangerous or underutilized? Expert Opin. Pharmacother. 22, 769\u2013777 (2021).","journal-title":"Expert Opin. Pharmacother."},{"key":"657_CR46","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40261-014-0238-6","volume":"34","author":"S Wason","year":"2014","unstructured":"Wason, S., Mount, D. & Faulkner, R. Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease. Clin. Drug Investig. 34, 845\u2013855 (2014).","journal-title":"Clin. Drug Investig."},{"key":"657_CR47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0009-9236(03)00094-8","volume":"74","author":"B Yang","year":"2003","unstructured":"Yang, B., Baughman, S. & Sullivan, J. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin. Pharmacol. Ther. 74, 85\u201394 (2003).","journal-title":"Clin. Pharmacol. Ther."},{"key":"657_CR48","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2165\/11599820-000000000-00000","volume":"51","author":"A Chakraborty","year":"2012","unstructured":"Chakraborty, A. et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1\u03b2 monoclonal antibody. Clin. Pharmacokinet. 51, e1\u2013e18 (2012).","journal-title":"Clin. Pharmacokinet."},{"key":"657_CR49","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1016\/j.clinthera.2011.01.008","volume":"32","author":"R Wortmann","year":"2010","unstructured":"Wortmann, R., MacDonald, P., Hunt, B. & Jackson, R. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin. Ther. 32, 2386\u20132397 (2010).","journal-title":"Clin. Ther."},{"issue":"Suppl. 1","key":"657_CR50","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/rheumatology\/kex453","volume":"57","author":"A Slobodnick","year":"2018","unstructured":"Slobodnick, A., Shah, B., Krasnokutsky, S. & Pillinger, M. H. Update on colchicine, 2017. Rheumatology 57 (Suppl. 1), i4\u2013i11 (2018).","journal-title":"Rheumatology"},{"key":"657_CR51","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/acr.22281","volume":"66","author":"J Curtis","year":"2014","unstructured":"Curtis, J. et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res. 66, 990\u2013997 (2014).","journal-title":"Arthritis Care Res."},{"key":"657_CR52","doi-asserted-by":"publisher","first-page":"870","DOI":"10.7326\/M20-1594","volume":"173","author":"M George","year":"2020","unstructured":"George, M. et al. Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis: a cohort study. Ann. Intern. Med. 173, 870\u2013878 (2020).","journal-title":"Ann. Intern. Med."},{"key":"657_CR53","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/annrheumdis-2017-211574","volume":"77","author":"H Yamanaka","year":"2018","unstructured":"Yamanaka, H. et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Ann. Rheum. Dis. 77, 270\u2013276 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"657_CR54","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/rheumatology\/kex156","volume":"56","author":"M Hui","year":"2017","unstructured":"Hui, M. et al. The British Society for Rheumatology guideline for the management of gout. Rheumatology 56, e1\u2013e20 (2017).","journal-title":"Rheumatology"},{"key":"657_CR55","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1136\/annrheumdis-2014-205577","volume":"74","author":"W-H Chung","year":"2015","unstructured":"Chung, W.-H. et al. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann. Rheum. Dis. 74, 2157\u20132164 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"657_CR56","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3899\/jrheum.121301","volume":"40","author":"K Pui","year":"2013","unstructured":"Pui, K., Gow, P. & Dalbeth, N. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. J. Rheumatol. 40, 872\u2013876 (2013).","journal-title":"J. Rheumatol."},{"key":"657_CR57","doi-asserted-by":"publisher","first-page":"706","DOI":"10.2169\/internalmedicine.44.706","volume":"44","author":"I Ohno","year":"2005","unstructured":"Ohno, I. et al. Frequency of gouty arthritis in patients with end-stage renal disease in Japan. Intern. Med. 44, 706\u2013709 (2005).","journal-title":"Intern. Med."},{"issue":"S10","key":"657_CR58","first-page":"265","volume":"68","author":"R Soriano","year":"2016","unstructured":"Soriano, R. et al. Serum uric acid lowering treatment appears unnecessary during hemodialysis [abstract 205]. Arthritis Rheumatol. 68 (S10), 265\u2013266 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"657_CR59","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001438","author":"M Arenas","year":"2020","unstructured":"Arenas, M., Soriano, R., Andr\u00e9s, M. & Pascual, E. Serum urate levels of hemodialyzed renal patients revisited. J. Clin. Rheum. https:\/\/doi.org\/10.1097\/RHU.0000000000001438 (2020).","journal-title":"J. Clin. Rheum."},{"key":"657_CR60","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/imj.14163","volume":"49","author":"E Yeo","year":"2019","unstructured":"Yeo, E., Palmer, S., Chapman, P., Frampton, C. & Stamp, L. Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study. Int. Med. J. 49, 838\u2013842 (2019).","journal-title":"Int. Med. J."},{"key":"657_CR61","first-page":"4183","volume":"68","author":"M Doogue","year":"2016","unstructured":"Doogue, M. et al. The pharmacokinetics of oxypurinol in patients treated with hemodialysis and allopurinol. Arthritis Rheum. 68, 4183\u20134184 (2016).","journal-title":"Arthritis Rheum."},{"key":"657_CR62","first-page":"1923","volume":"32","author":"J Alvarez-Nemegyei","year":"2005","unstructured":"Alvarez-Nemegyei, J., Cen-Piste, J. C., Medina-Escobedo, M. & Villanueva-Jorge, S. Factors associated with musculoskeletal disability and chronic renal failure in clinically diagnosed primary gout. J. Rheumatol. 32, 1923\u20131927 (2005).","journal-title":"J. Rheumatol."},{"key":"657_CR63","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1002\/jcph.939","volume":"57","author":"E Rutherford","year":"2017","unstructured":"Rutherford, E. et al. An open-label dose-finding study of allopurinol to target defined reduction in urate levels in hemodialysis patients. J. Clin. Pharmacol. 57, 1409\u20131414 (2017).","journal-title":"J. Clin. Pharmacol."},{"key":"657_CR64","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1136\/annrheumdis-2013-204195","volume":"74","author":"CN Son","year":"2015","unstructured":"Son, C. N., Jeong, H. J., Kim, J. M., Kim, H. S. & Kim, S. H. Febuxostat may be usefully utilized for allopurinol-refractory hyperuricemia in gout treatment of dialysis patients or those in stage 4 chronic kidney disease (CKD). Ann. Rheum. Dis. 74, 538 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"657_CR65","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1053\/j.ajkd.2016.07.001","volume":"68","author":"D Lim","year":"2016","unstructured":"Lim, D. et al. Febuxostat in hyperuricemic patients with advanced CKD. Am. J. Kidney Dis. 68, 819\u2013821 (2016).","journal-title":"Am. J. Kidney Dis."},{"key":"657_CR66","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00228-016-2133-y","volume":"73","author":"D Wright","year":"2017","unstructured":"Wright, D. et al. A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. Eur. J. Clin. Pharmacol. 73, 71\u201378 (2017).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"657_CR67","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1002\/art.34488","volume":"64","author":"L Stamp","year":"2012","unstructured":"Stamp, L. et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome. A proposed safe starting dose of allopurinol. Arthritis Rheum. 64, 2529\u20132536 (2012).","journal-title":"Arthritis Rheum."},{"key":"657_CR68","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","volume":"76","author":"L Stamp","year":"2017","unstructured":"Stamp, L. et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann. Rheum. Dis. 76, 1522\u20131528 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"657_CR69","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1136\/annrheumdis-2017-211873","volume":"76","author":"L Stamp","year":"2017","unstructured":"Stamp, L. et al. Allopurinol dose escalation to achieve serum urate below 6 mg\/dl: an open label extension study. Ann. Rheum. Dis. 76, 2065\u20132070 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"657_CR70","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/art.39654","volume":"68","author":"K Saag","year":"2016","unstructured":"Saag, K. et al. Impact of febuxostat on renal function in gout subjects with moderate-to-severe renal impairment. Arthritis Rheum. 68, 2035\u20132043 (2016).","journal-title":"Arthritis Rheum."},{"key":"657_CR71","first-page":"254","volume":"46","author":"E Paschou","year":"2016","unstructured":"Paschou, E. et al. Febuxostat hypersensitivity: another cause of DRESS syndrome in chronic kidney disease? Eur. Ann. Allergy Clin. Immunol. 46, 254\u2013255 (2016).","journal-title":"Eur. Ann. Allergy Clin. Immunol."},{"key":"657_CR72","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11926-017-0626-z","volume":"19","author":"M Adwan","year":"2017","unstructured":"Adwan, M. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome and the rheumatologist. Curr. Rheumatol. Rep. 19, 3 (2017).","journal-title":"Curr. Rheumatol. Rep."},{"key":"657_CR73","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrrheum.2015.132","volume":"12","author":"LK Stamp","year":"2016","unstructured":"Stamp, L. K., Day, R. O. & Yun, J. Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nat. Rev. Rheumatol. 12, 235\u2013242 (2016).","journal-title":"Nat. Rev. Rheumatol."},{"key":"657_CR74","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.4049\/jimmunol.1302306","volume":"192","author":"J Yun","year":"2014","unstructured":"Yun, J. et al. Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01. J. Immunol. 192, 2984\u20132993 (2014).","journal-title":"J. Immunol."},{"key":"657_CR75","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/cea.12184","volume":"43","author":"J Yun","year":"2013","unstructured":"Yun, J. et al. Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response. Clin. Exp. Allergy 43, 1246\u20131255 (2013).","journal-title":"Clin. Exp. Allergy"},{"key":"657_CR76","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11883-019-0794-6","volume":"21","author":"S Ali","year":"2019","unstructured":"Ali, S., Dave, N., Virani, S. & Navaneethan, S. Primary and secondary prevention of cardiovascular disease in patients with chronic kidney disease. Curr. Atheroscler. Rep. 21, 32 (2019).","journal-title":"Curr. Atheroscler. Rep."},{"key":"657_CR77","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"W White","year":"2018","unstructured":"White, W. et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N. Engl. J. Med. 378, 1200\u20131210 (2018).","journal-title":"N. Engl. J. Med."},{"key":"657_CR78","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","volume":"396","author":"IS Mackenzie","year":"2020","unstructured":"Mackenzie, I. S. et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet 396, 1745\u20131757 (2020).","journal-title":"Lancet"},{"key":"657_CR79","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1002\/art.40583","volume":"70","author":"H Choi","year":"2018","unstructured":"Choi, H., Neogi, T., Stamp, L., Dalbeth, N. & Terkeltaub, R. New perspectives in rheumatology: implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial and the associated Food and Drug Administration public safety alert. Arthritis Rheumatol. 70, 1702\u20131709 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"657_CR80","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-019-0115-y","volume":"5","author":"N Dalbeth","year":"2019","unstructured":"Dalbeth, N. et al. Gout. Nat. Rev. Dis. Primers 5, 69 (2019).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"657_CR81","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.27327","volume":"62","author":"R Terkeltaub","year":"2010","unstructured":"Terkeltaub, R. et al. High versus low dosing of oral colchicine for early acute gout flare. Arthritis Rheum. 62, 1060\u20131068 (2010).","journal-title":"Arthritis Rheum."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-021-00657-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-021-00657-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-021-00657-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T12:04:42Z","timestamp":1632312282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-021-00657-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,30]]},"references-count":81,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["657"],"URL":"https:\/\/doi.org\/10.1038\/s41584-021-00657-4","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,30]]},"assertion":[{"value":"28 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.K.C. declares that he has received consulting fees from Takeda and Selecta (less than $10,000 each), research support from Horizon on an unrelated project, and is a member of the Data Safety Monitoring Committee for the VA-CSP 594 STOP GOUT clinical trial. R.T. declares that he has received consulting fees from AstraZeneca, Genentech, Horizon, SOBI (less than $10,000 each) and Selecta (more than $10,000). The other authors declare no competing interests. G-CAN is supported at arm\u2019s length by unrestricted by grants from pharma companies including AstraZeneca, Horizon and LG within the past 12 months. No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}